H-1B sponsorship profile: Denali Therapeutics Inc. Across U.S. Department of Labor LCA disclosures, Denali Therapeutics Inc filed 43 Labor Condition Applications covering 43 H-1B worker positions between fiscal year 2023 and fiscal year 2026. The employer’s DOL certification rate sits at 93% (40 certified of 43 filed), a useful proxy for how cleanly their prevailing-wage attestations pass the Labor Department’s preliminary review before USCIS adjudication.

Compensation spread. Offered wages on Denali Therapeutics Inc’s H-1B petitions range from $75,000 at the low end to $265,000 at the high end, with a petition-weighted average of $154,694. That range reflects the mix of occupations the company sponsors, led by Scientist (6 petitions at $148,219 avg), followed by Senior Scientist, Large Molecule Formulation Development and Director, Clinical Operations. H-1B salaries reported on LCAs must meet or exceed the DOL prevailing wage for the role and worksite, so the spread also tracks wage-level geography and seniority.

Geographic footprint. Denali Therapeutics Inc is headquartered in South San Francisco, CA under NAICS code 325412, and places H-1B workers across 3 states, most heavily in CA, UT, NC. Combined, these signals give a granular view of how one employer uses the H-1B program, volume, approval cleanliness, wage posture, and where the jobs actually sit on the map.

Where Denali Therapeutics Inc ranks. By H-1B petition volume, Denali Therapeutics Inc is #5,367 of 119,880 employers nationally and #781 of 22,893 employers headquartered in CA. Both ranks are computed live from the same underlying petition counts, not a separate estimate.